||Last Updated: Nov 17th, 2006 - 22:35:04
A dog in home may worsen asthma in children
A new study from researchers at the Keck School of Medicine of the University of Southern California (USC) suggests that having a dog in the home may worsen the response to air pollution of a child with asthma. The study was published this week in the online edition of Environmental Health Perspectives, the journal of the National Institute of Environmental Health Sciences.
Aug 29, 2006, 21:08
PEAK Trial: Inhaled steroids do not prevent chronic asthma
Daily treatment with inhaled corticosteroids can reduce breathing problems in pre-school-aged children at high risk for asthma but they do not prevent the development of persistent asthma in these children, according to new results from the Childhood Asthma Research and Education (CARE) Network supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
May 11, 2006, 17:36
Telithromycin antibiotic could help in asthma attack
A relatively new kind of antibiotic has been found to provide faster relief from an asthma attack, but more research is necessary before the drug can be prescribed, says a study.
Apr 15, 2006, 18:08
Tomatoes, carrots can cut asthma risk
Eating plenty of tomatoes, carrots and leafy green vegetable could help in reducing asthma risk in women, says a study.
Mar 19, 2006, 20:14
Inhaled steroid may work better for normal-weight people
As the nation's collective waistline has swelled in recent decades, rates of asthma diagnoses also have accelerated. Indeed, much research has affirmed a link between the two conditions. But doctors also recognize that asthma may not behave the same way among people who have different body types. With a variety of asthma medications on the market, what kinds work best for lean people and what kinds work best for obese people? The answer may be different for each group. A new study suggests that people who are overweight or obese may have better results with the prescription pill sold as Singulair than with a type of inhaled steroid, while leaner people may have better luck with an inhaled steroid, called beclomethasone and sold as beclovent, vanceril and other brand names. The findings appear in the new issue of the European Respiratory Journal.
Feb 23, 2006, 12:18
Female foetus could increase expectant woman's asthma
Asthmatic women pregnant with girls are more likely to experience severe asthma symptoms than those carrying a male foetus, says a study.
Feb 3, 2006, 15:38
Childhood Asthma Affecting More than Just Breathing
Recent research has shown that kids with asthma may also be at risk for psychological problems such as depression, anxiety, and problems in their social lives including peer interactions. This study, recently published in the Journal of Child and Adolescent Psychiatric Nursing, is one of the first to examine relationships among asthma, anxiety and depression, and several aspects of social functioning in urban children.
Oct 26, 2005, 23:57
Omalizumab has long-term benefits in severe allergic asthma
New long-term data show that Xolair® (omalizumab), a first-in-class monoclonal antibody for treating severe allergic asthma, helped patients to maintain control of their disease and was safe and well-tolerated in studies lasting more than three years. The data were presented at the European Respiratory Society (ERS) congress in Denmark, along with results from seven clinical studies showing that Xolair significantly improved the lung function of patients.
Sep 29, 2005, 20:49
CD23 structure revealed by NMR spectroscopy
The structure of a molecule that regulates levels of the key antibody involved in allergic reactions and asthma, IgE, has been revealed by researchers from Oxford University and King’s College London. The study, published in Journal of Experimental Medicine, will help in the discovery of drugs to treat these two conditions.
Sep 21, 2005, 19:22
Bacteria in Household Dust May Trigger Asthma
New research shows that bacteria lurking in household dust produce chemicals that may trigger asthma and asthma-related symptoms such as wheezing. These bacterial chemicals, called endotoxins, particularly those found on bedroom floors, were linked with increased respiratory problems in adults. This study, supported by the National Institute of Environmental Health Sciences (NIEHS), a part of the National Institutes of Health, is the first nationwide study of endotoxins in the household environment, and it involved analysis of more than 2,500 dust samples from 831 homes across the U.S.
Sep 9, 2005, 15:30
Emotion processing centers in brain linked with asthma
The mere mention of a stressful word like "wheeze" can activate two brain regions in asthmatics during an attack, and this brain activity may be associated with more severe asthma symptoms, according to a study by University of Wisconsin-Madison researchers and collaborators.
Aug 29, 2005, 22:15
Investigators Reveal a Key to Viral-Induced Asthma
Researchers have discovered a new way to distinguish virus-induced asthma from that of allergen-caused disease based on a study of 59 asthma patients who were experiencing an acute exacerbation
Aug 15, 2005, 17:59
T lymphocytes cause airway thickening in asthma
MUHC scientists have discovered that our body's own defense mechanism causes some of the most serious asthma symptoms. The study by MUHC researchers Dr. David Ramos-Barbón, Dr. Elizabeth Fixman and Dr. James Martin, published in a recent issue of Journal of Clinical Investigation (JCI), reveals that T lymphocytes--our body's defense cells--are responsible for the airway thickening, which increases the chances of a dangerous asthma attack.
Aug 14, 2005, 14:30
Inhale magnesium sulphate along with beta-2-agonists during asthma attacks
Severe asthma attacks can be life threatening and intravenous magnesium sulphate is known to help, but inhaling nebulised magnesium sulphate can also improve lung function.
Jul 20, 2005, 15:07
Findings offer therapeutic potential for human asthma treatment
Disruption of a single gene, Nrf2, plays a critical role in determining the susceptibility to asthma. A research team led by Shyam Biswal, PhD, at the Johns Hopkins Bloomberg School of Public Health found the absence of Nrf2 exacerbated allergen-mediated asthma in mice models. The study’s findings, published in the July 4, 2005, edition of the Journal of Experimental Medicine, may hold therapeutic potential for the treatment of human asthma.
Jul 6, 2005, 13:24
Key milestone in antifungal treatment for severe asthma
University of Manchester researchers announced today that they have reached a key milestone in their study of the antifungal treatment of asthma.
Jun 16, 2005, 18:00
Another rung on the Asthma ladder
Xolair® halves rate of severe exacerbations and significantly improves quality of life in patients at risk of life-threatening asthma attacks
May 29, 2005, 16:26
Cockroach Allergens Have Greatest Impact on Childhood Asthma
New results from a nationwide study on factors that affect asthma in inner-city children show that cockroach allergen appears to worsen asthma symptoms more than either dust mite or pet allergens.
Apr 8, 2005, 04:11
Asthma patients' immune systems respond differently with allergies
Researchers from the University of Chihuahua in Mexico report that immune systems of patients with asthma responded differently to a common laboratory challenge, depending on whether their white blood cells had been obtained during a time when they were suffering from common season allergic rhinitis or when they were free of such allergic symptoms.
Apr 3, 2005, 10:33
Zileuton Shows Significant Benefit in Prevention and Chronic Treatment of Asthma
Critical Therapeutics, Inc. (Nasdaq: CRTX), today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the Company's investigational asthma drug ZYFLO(R) Filmtab(R) (zileuton tablets). Approval of the sNDA would allow Critical Therapeutics to begin marketing its version of ZYFLO in the United States.
Apr 2, 2005, 08:39
Mometasone furoate Shows Substantial Improvement in Lung Function in Persistent Asthma
Schering-Plough Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the use of ASMANEX® TWISTHALER® 220 mcg (mometasone furoate inhalation powder) for the first-line maintenance treatment of asthma as preventive therapy in patients 12 years of age and older.
Mometasone furoate is also the only inhaled asthma controller therapy approved for once daily initiation and management of asthma in patients previously treated with bronchodilators alone or inhaled corticosteroids. Clinical studies with Mometasone furoate have shown substantial improvement in lung function, decreased use of rescue medication, decreased incidence of nighttime awakenings and significant improvements in daytime symptoms such as coughing and wheezing.
Apr 1, 2005, 09:14
Association found between high body mass index (BMI) and asthma
In a cohort of New Zealand children who were followed from birth to age 26, overweight, expressed as higher body mass index, was significantly associated with asthma wheeze in females, but not in males.
Mar 1, 2005, 17:34
Pulmonary complications after nonthoracic surgery are more frequent than cardiac complications
According to the authors, pulmonary complications after nonthoracic surgery are more frequent than cardiac complications and are associated with a greater increase in hospital length of stay.
Mar 1, 2005, 17:34
Montelukast significantly reduced Asthma exacerbations in young children
Montelukast, a leukotriene receptor antagonist, significantly decreased the rate of exacerbations and lengthened the time between exacerbations in 2- to 5-year-old asthma patients who suffered from intermittent symptoms. The researchers pointed out that montelukast significantly reduced by almost 32 percent the rate of exacerbations over 12 months, as compared with results from patients on placebo. The average rate of exacerbation episodes was 1.60 episodes per patient per year, compared with 2.34 for placebo. (Leukotrienes are biologically active compounds that function as chemical mediators. They have vasoactive properties that help regulate allergic and inflammatory reactions. Medical antagonists are designed to counteract specific functions.) According to the authors, asthma usually begins and has its greatest prevalence in children younger than 5 years.
Feb 16, 2005, 19:33
Role for the A1 adenosine receptor in protecting against asthma
Levels of the signaling molecule adenosine are increased in the lungs of asthmatics, and elevations of adenosine correlate with the degree of airway inflammation, suggesting that adenosine may play a provocative role in acute asthma attacks. Therefore much research has been focused on drugs that may potentially interact with known adenosine receptors – the activation of which can have proinflammatory or anti-inflammatory effects, depending on the receptor type. Theophylline, the most widely prescribed drug for the treatment of airway disease worldwide, is able to block both pro- and anti-inflammatory actions of adenosine, potentially decreasing its efficiency. Researchers are now focused on determining the role of each adenosine receptor so that they may design drugs to interact with specific receptors and reduce airway inflammation.
Jan 4, 2005, 19:35
High-risk asthma patients reduce asthma medication use in days after hospitalization
In a study of high-risk patients with severe asthma who were hospitalized for serious exacerbations, researchers showed that within 7 days of discharge their use of prescribed inhaled corticosteroids and oral steroids had fallen rapidly to approximately 50 percent of their prescribed dose. The investigators measured post-hospital adherence in 52 inner city asthmatics by means of electronic medication monitors, self-report, canister weight (for inhaled corticosteroids) and pill counts (for oral corticosteroids). The researchers noted that their results provided strong evidence that even under optimal conditions with free medications and intensive inpatient education, discontinuation of both inhaled corticosteroids and oral corticosteroids was common within 7 days of discharge from the hospital.
Dec 16, 2004, 16:37